Mariëlle van Aalst1, Hannah M Garcia Garrido1, Josephine van der Leun1, Bob Meek2, Ester M M van Leeuwen3, Mark Löwenberg4, Geert R D'Haens4, Cyriel Y I Ponsioen4, Martin P Grobusch1,5, Abraham Goorhuis1. 1. Centre of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centres, Nieuwegein. 2. Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein. 3. Department of Experimental Immunology, Amsterdam University Medical Centres, University of Amsterdam, The Netherlands. 4. Department of Gastroenterology, Amsterdam University Medical Centres, University of Amsterdam, The Netherlands. 5. Institute of Tropical Medicine, University of Tübingen, Germany.
Abstract
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk of invasive pneumococcal infections. Therefore, vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 2 months later is recommended. However, the level of immunogenicity induced by this vaccination schedule in IBD patients with and without immunosuppressive medication remains unclear. METHODS: We prospectively assessed the immunogenicity of PCV13 followed by PPSV23 in IBD patients by measuring serotype-specific pneumococcal immunoglobulin G antibody concentrations at baseline and 4-8 weeks postvaccination. Response to vaccination was defined as a postvaccination antibody concentration ≥1.3 μg/mL for 70% of the measured serotypes. We analyzed the immunogenic effect of 4 different medication regimens: (1) conventional immunomodulators (ie, oral prednisolone >10 mg/day, thiopurines, methotrexate); (2) anti-tumor necrosis factor agents; (3) combination therapy; and (4) no treatment with immunosuppressive agents (control group). RESULTS: One hundred forty-one IBD patients were included, of whom 37 were controls. Adequate response to vaccination was 59% (61/104) in patients using immunosuppressive agents (groups 1-3) vs 81% (30/37) in controls (odds ratio, 0.33 [95% confidence interval, .13-.82]). A combination of different immunosuppressive drugs most severely impaired the immune response to pneumococcal vaccination (response, 52% [15/29]). CONCLUSIONS: Although the sequential vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic, and thus beneficial in the majority of IBD patients, those receiving immunosuppressive agents, and especially those receiving combination therapy, have an impaired immune response compared to controls. Therefore, preferably, vaccinations should be administered before the initiation of immunosuppressive therapy. CLINICAL TRIALS REGISTRATION: Dutch trial register #6315.
BACKGROUND:Patients with inflammatory bowel disease (IBD) are at increased risk of invasive pneumococcal infections. Therefore, vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) 2 months later is recommended. However, the level of immunogenicity induced by this vaccination schedule in IBDpatients with and without immunosuppressive medication remains unclear. METHODS: We prospectively assessed the immunogenicity of PCV13 followed by PPSV23 in IBDpatients by measuring serotype-specific pneumococcal immunoglobulin G antibody concentrations at baseline and 4-8 weeks postvaccination. Response to vaccination was defined as a postvaccination antibody concentration ≥1.3 μg/mL for 70% of the measured serotypes. We analyzed the immunogenic effect of 4 different medication regimens: (1) conventional immunomodulators (ie, oral prednisolone >10 mg/day, thiopurines, methotrexate); (2) anti-tumor necrosis factor agents; (3) combination therapy; and (4) no treatment with immunosuppressive agents (control group). RESULTS: One hundred forty-one IBDpatients were included, of whom 37 were controls. Adequate response to vaccination was 59% (61/104) in patients using immunosuppressive agents (groups 1-3) vs 81% (30/37) in controls (odds ratio, 0.33 [95% confidence interval, .13-.82]). A combination of different immunosuppressive drugs most severely impaired the immune response to pneumococcal vaccination (response, 52% [15/29]). CONCLUSIONS: Although the sequential vaccination schedule of PCV13 followed by PPSV23 is safe, immunogenic, and thus beneficial in the majority of IBDpatients, those receiving immunosuppressive agents, and especially those receiving combination therapy, have an impaired immune response compared to controls. Therefore, preferably, vaccinations should be administered before the initiation of immunosuppressive therapy. CLINICAL TRIALS REGISTRATION: Dutch trial register #6315.
Authors: Hannah M Garcia Garrido; Jenny L Schnyder; Michael W T Tanck; Albert Vollaard; René Spijker; Martin P Grobusch; Abraham Goorhuis Journal: EClinicalMedicine Date: 2020-11-23
Authors: Jennifer L Jones; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Eric I Benchimol Journal: J Can Assoc Gastroenterol Date: 2021-07-29
Authors: Ralley E Prentice; Clarissa Rentsch; Aysha H Al-Ani; Eva Zhang; Douglas Johnson; John Halliday; Robert Bryant; Jacob Begun; Mark G Ward; Peter J Lewindon; Susan J Connor; Simon Ghaly; Britt Christensen Journal: GastroHep Date: 2021-07-23
Authors: Marco Vincenzo Lenti; Caterina Mengoli; Marta Vernero; Nicola Aronico; Laura Conti; Federica Borrelli de Andreis; Sara Cococcia; Antonio Di Sabatino Journal: Front Immunol Date: 2020-03-23 Impact factor: 7.561
Authors: Gaurav Syal; Mariastella Serrano; Animesh Jain; Benjamin L Cohen; Florian Rieder; Christian Stone; Bincy Abraham; David Hudesman; Lisa Malter; Robert McCabe; Stefan Holubar; Anita Afzali; Adam S Cheifetz; Jill K J Gaidos; Alan C Moss Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325